AACR 2021 | Combining EGFR and VEGF inhibitors for NSCLC
Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential role of dual EGFR-VEGF pathway inhibition in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). Dr Le describes the findings of in vitro research which has shown that VEGF and EGFR pathways share common downstream signaling, as well as clinical studies, such as the RELAY trial (NCT02411448), which have demonstrated that addition of anti-VEGF drugs to EGFR tyrosine kinase inhibitors can improve outcomes. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Xiuning Le, MD, PhD, has received consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb and Celgene; and has received research funding from Eli Lilly and Boehringer Ingelheim.
